ThisCART19 cells

BIOLOGICAL2 trials

Sponsors

Fundamenta Therapeutics, Ltd.

Conditions

B Cell MalignancyB-cell Malignancy

Phase 1

Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies

Fundamenta Therapeutics, Ltd.B Cell Malignancy

Start: 2020-05-09End: 2023-10-24Target: 30Updated: 2022-01-11

Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma

Fundamenta Therapeutics, Ltd.B-cell Malignancy

Start: 2021-10-25End: 2024-10-24Target: 20Updated: 2021-11-04

Related Papers

A study of a new mechanism: Intracellular retention allo-CART safety and efficacy for extranodal bulky B-NHL.

Journal of Clinical Oncology2024-06-01

Abstract LB341: Clinical validation and mechanistic insights of ThisCART: A novel allogeneic platform enhancing CAR-T signaling via intracellular TCRαβ/CD3 retention

Cancer Research2024-04-05

S264: PRELIMINARY ANALYSES OF A NON-GENE-EDITING ALLOGENTIC CAR-T IN CD19+ RELAPSED OR REFRACTORY NON-HODGIN’S LYMPHOMA

HemaSphere2022-06-012 citations